$ANEB
Anebulo Pharmaceuticals, Inc.

2023 Q3 Form 10-K Financial Statement

#000149315223033452 Filed on September 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.273M $1.080M $6.180M
YoY Change -8.27% -10.55% 59.7%
% of Gross Profit
Research & Development $1.270M $1.420M $5.600M
YoY Change 3.8% 27.0% 89.1%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.544M $2.490M $11.78M
YoY Change -2.62% 7.07% 72.5%
Operating Profit -$2.544M -$11.78M
YoY Change -2.62% 72.5%
Interest Expense $55.20K $90.00K $90.00K
YoY Change 1127.83%
% of Operating Profit
Other Income/Expense, Net $62.86K -$90.00K $51.26K
YoY Change 29830.95% 1860.78% 822.79%
Pretax Income -$2.481M -$2.500M -$11.73M
YoY Change -5.02% 7.63% 71.85%
Income Tax
% Of Pretax Income
Net Earnings -$2.500M -$2.500M -$11.73M
YoY Change -4.28% 7.63% 71.89%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10 $0.47
Diluted Earnings Per Share -$0.10 -$0.10 $0.47
COMMON SHARES
Basic Shares Outstanding 25.63M shares 25.63M shares 25.07M shares
Diluted Shares Outstanding 25.63M shares 25.07M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.521M $11.25M $11.25M
YoY Change -55.65% -22.67% -22.67%
Cash & Equivalents $8.521M $11.25M
Short-Term Investments
Other Short-Term Assets $527.3K $420.0K $420.0K
YoY Change -12.36% -59.26% -59.26%
Inventory
Prepaid Expenses $527.3K $422.7K
Receivables
Other Receivables
Total Short-Term Assets $9.048M $11.67M $11.67M
YoY Change -54.34% -25.09% -25.09%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.00 $151.00 $0.00
YoY Change -180.0% 15000.0%
TOTAL ASSETS
Total Short-Term Assets $9.048M $11.67M $11.67M
Total Long-Term Assets $4.00 $151.00 $0.00
Total Assets $9.048M $11.67M $11.67M
YoY Change -54.34% -25.09% -25.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $565.9K $534.5K $530.0K
YoY Change 8.11% 40.36% 39.17%
Accrued Expenses $150.6K $534.3K $530.0K
YoY Change -13.79% 305.65% 302.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $716.6K $1.070M $1.070M
YoY Change 2.63% 108.77% 108.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $716.6K $1.070M $1.070M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $716.6K $1.069M $1.070M
YoY Change 2.63% 108.53% 108.77%
SHAREHOLDERS EQUITY
Retained Earnings -$59.70M -$57.20M
YoY Change 24.16% 25.8%
Common Stock $25.63K $25.63K
YoY Change 0.0% 9.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.331M $10.60M $10.60M
YoY Change
Total Liabilities & Shareholders Equity $9.048M $11.67M $11.67M
YoY Change -54.34% -25.09% -25.09%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2023
OPERATING ACTIVITIES
Net Income -$2.500M -$2.500M -$11.73M
YoY Change -4.28% 7.63% 71.89%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.727M -$2.850M -$9.683M
YoY Change 34.07% 42.55% 78.09%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.647M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -70.00K $6.382M
YoY Change
NET CHANGE
Cash From Operating Activities -$2.727M -2.850M -$9.683M
Cash From Investing Activities
Cash From Financing Activities -70.00K $6.382M
Net Change In Cash -$2.727M -2.920M -$3.301M
YoY Change -158.45% 46.05% -39.29%
FREE CASH FLOW
Cash From Operating Activities -$2.727M -$2.850M -$9.683M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001815974
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q2 ANEB Prepaid Research And Development
PrepaidResearchAndDevelopment
usd
CY2022Q2 ANEB Deferred Tax Assets Capitalized Expenditures
DeferredTaxAssetsCapitalizedExpenditures
usd
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40388
CY2023 dei Entity Registrant Name
EntityRegistrantName
ANEBULO PHARMACEUTICALS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1170950
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1017 Ranch Road 620 South
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 107
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Lakeway
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78734
CY2023 dei City Area Code
CityAreaCode
(512)
CY2023 dei Local Phone Number
LocalPhoneNumber
598-0931
CY2023 dei Security12b Title
Security12bTitle
Common Stock
CY2023 dei Trading Symbol
TradingSymbol
ANEB
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Public Float
EntityPublicFloat
9468006 usd
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25633217 shares
CY2023 dei Auditor Firm
AuditorFirmId
274
CY2023 dei Auditor Name
AuditorName
EISNERAMPER LLP
CY2023 dei Auditor Location
AuditorLocation
Iselin, New Jersey
CY2023Q2 us-gaap Cash
Cash
11247403 usd
CY2022Q2 us-gaap Cash
Cash
14548471 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
422748 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1030960 usd
CY2023Q2 us-gaap Assets
Assets
11670151 usd
CY2022Q2 us-gaap Assets
Assets
15579431 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
534545 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
380828 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
534256 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
131703 usd
CY2023Q2 us-gaap Liabilities
Liabilities
1068801 usd
CY2022Q2 us-gaap Liabilities
Liabilities
512531 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25633217 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25633217 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23344567 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23344567 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
25634 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
23345 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
67777757 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60513258 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57202041 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45469703 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10601350 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15066900 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11670151 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15579431 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5600197 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2961538 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6183402 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3869636 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
11783599 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
6831174 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-11783599 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-6831174 usd
CY2023 us-gaap Interest Income Other
InterestIncomeOther
92407 usd
CY2022 us-gaap Interest Income Other
InterestIncomeOther
7332 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41146 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1777 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
51261 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5555 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-11732338 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-6825619 usd
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25074481 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25074481 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23344567 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23344567 shares
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.47
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.29
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
21411858 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
480661 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-6825619 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15066900 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15066900 usd
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
317083 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6329665 usd
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
52400 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
884723 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-11732338 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10601350 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10601350 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-11732338 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-6825619 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
884723 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
480661 usd
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-608212 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-636886 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
153717 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
270780 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
402553 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
118 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9683133 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5437174 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6646748 usd
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
317083 usd
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
52400 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6382065 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3301068 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5437174 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14548471 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19985645 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11247403 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14548471 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-11732338 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57202041 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zAiTMpnjQsoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zimKohwzifi1">Use of estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the audited financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 usd
CY2022Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 usd
CY2023 us-gaap Payments For Rent
PaymentsForRent
15100 usd
CY2022 us-gaap Payments For Rent
PaymentsForRent
14400 usd
CY2023 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency.
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.210 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.210 pure
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y3M18D
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
391750 usd
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
790343 usd
CY2022Q2 ANEB Prepaid Research And Development
PrepaidResearchAndDevelopment
210865 usd
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
30998 usd
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
29752 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
422748 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1030960 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.54
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y8M12D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
96734 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
829112 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.29
CY2023Q2 ANEB Accrued Research And Development
AccruedResearchAndDevelopment
344135 usd
CY2022Q2 ANEB Accrued Research And Development
AccruedResearchAndDevelopment
105980 usd
CY2023Q2 ANEB Accrued Payroll Related Expenses
AccruedPayrollRelatedExpenses
190121 usd
CY2022Q2 ANEB Accrued Payroll Related Expenses
AccruedPayrollRelatedExpenses
25723 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
534256 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
131703 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2866860 usd
CY2022Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1843175 usd
CY2023Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
272162 usd
CY2022Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
265741 usd
CY2023Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
298135 usd
CY2022Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
120576 usd
CY2023Q2 ANEB Deferred Tax Assets Capitalized Expenditures
DeferredTaxAssetsCapitalizedExpenditures
1248760 usd
CY2023Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4685917 usd
CY2022Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2229492 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4685917 usd
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2229492 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2500000 usd
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
13700000 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.50 pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1911459 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.63
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y4M24D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
172654 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.31
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
24000 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.18
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
10800 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.00
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2049313 shares
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
63458 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
884723 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
480661 usd
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4313963 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1911459 shares

Files In Submission

Name View Source Status
aneb-20230630_pre.xml Edgar Link unprocessable
0001493152-23-033452-index-headers.html Edgar Link pending
0001493152-23-033452-index.html Edgar Link pending
0001493152-23-033452.txt Edgar Link pending
0001493152-23-033452-xbrl.zip Edgar Link pending
aneb-20230630.xsd Edgar Link pending
ex23-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
form10-k_010.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
aneb-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aneb-20230630_cal.xml Edgar Link unprocessable
aneb-20230630_def.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending